TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pain Reactivity to Non-pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit
Brief Summary: Switzerland is having one of the highest premature rates in Europa and most of the preterm neonates need neonatal intensive care. Up to 80% of the analgesic used in neonatal intensive care units are either "off label used" or "non-licensed" used. As an alternative approach non-pharmacological interventions for pain prevention and relief are increasingly being recommended for the prevention and treatment of mild and moderate pain in this population.

This multicenter pilot study will use a randomized three group,repeated measures design.

The primary aims of this study of premature neonates are to:

1.) Estimate effect sizes for the impact of the proposed interventions(facilitated tucking alone, sucrose alone and sucrose in combination with tucking)on pain reactivity.

2.) Examine the impact of gestational age on the estimates of efficacy 3.) Examine the impact of the numbers of painful procedures the infant experiences and the concurrent use of analgesic medications on the estimates of efficacy


Options:
A: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
B: Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: 24% oral sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: 24% oral sucrose | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: DRUG; Name: 24% oral sucrose; Assigned to Arm(s): 24% oral sucrose
C: Arm Label: Breast Milk; Type: ACTIVE_COMPARATOR; Interventions: Other: Breast Human Milk | Arm Label: 24 %Sucrose; Type: OTHER; Interventions: Other: 24 % Sucrose | Intervention Type: OTHER; Name: Breast Human Milk; Assigned to Arm(s): Breast Milk | Intervention Type: OTHER; Name: 24 % Sucrose; Assigned to Arm(s): 24 %Sucrose
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 25% Sucrose | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: facilitated tucking | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sucrose and facilitated tucking | Intervention Type: PROCEDURE; Name: 25% Sucrose; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: facilitated tucking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Sucrose and facilitated tucking; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pain Reactivity to Non-pharmacological Interventions Across Repeated Routine Heel-Sticks in Preterm Infants in a Neonatal Intensive Care Unit
Brief Summary: Switzerland is having one of the highest premature rates in Europa and most of the preterm neonates need neonatal intensive care. Up to 80% of the analgesic used in neonatal intensive care units are either "off label used" or "non-licensed" used. As an alternative approach non-pharmacological interventions for pain prevention and relief are increasingly being recommended for the prevention and treatment of mild and moderate pain in this population.

This multicenter pilot study will use a randomized three group,repeated measures design.

The primary aims of this study of premature neonates are to:

1.) Estimate effect sizes for the impact of the proposed interventions(facilitated tucking alone, sucrose alone and sucrose in combination with tucking)on pain reactivity.

2.) Examine the impact of gestational age on the estimates of efficacy 3.) Examine the impact of the numbers of painful procedures the infant experiences and the concurrent use of analgesic medications on the estimates of efficacy


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 25% Sucrose | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: facilitated tucking | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sucrose and facilitated tucking | Intervention Type: PROCEDURE; Name: 25% Sucrose; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: facilitated tucking; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Sucrose and facilitated tucking; Assigned to Arm(s): 3
B: Arm Label: oral sucrose solution; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Steril water | Arm Label: steril water; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Oral sucrose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral sucrose solution; Assigned to Arm(s): steril water | Intervention Type: DIETARY_SUPPLEMENT; Name: Steril water; Assigned to Arm(s): oral sucrose solution
C: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.


Options:
A: Arm Label: Besifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Besifloxacin | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle (Placebo) | Intervention Type: DRUG; Name: Besifloxacin; Assigned to Arm(s): Besifloxacin | Intervention Type: DRUG; Name: Vehicle (Placebo); Assigned to Arm(s): Vehicle
B: Arm Label: Gatifloxacin 0.5% Eye Drops; Type: EXPERIMENTAL; Interventions: Drug: Gatifloxacin 0.5% eye drops | Arm Label: Placebo Eye Drops; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo eye drops | Intervention Type: DRUG; Name: Gatifloxacin 0.5% eye drops; Assigned to Arm(s): Gatifloxacin 0.5% Eye Drops | Intervention Type: DRUG; Name: placebo eye drops; Assigned to Arm(s): Placebo Eye Drops
C: Arm Label: ISV-403; Type: EXPERIMENTAL; Interventions: Drug: ISV-403 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: ISV-403; Assigned to Arm(s): ISV-403 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: Moxifloxacin AF; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Moxifloxacin AF Vehicle | Intervention Type: DRUG; Name: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%; Assigned to Arm(s): Moxifloxacin AF | Intervention Type: OTHER; Name: Moxifloxacin AF Vehicle; Assigned to Arm(s): Vehicle

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years
Brief Summary: The regulatory effects of the autonomic nervous system (ANS) concern almost all organs which permanently feed information back to this global biological vigilance system controlling allostasis. Heart rate fluctuations are highly dependent on ANS control, making the heart one of the best indicators of ANS activity.

Low ANS activity level is associated with severe cardiac and cerebral events, as well as to death from any cause in the general population.

This PROOF study was hence designed to evaluate ANS activity levels among a healthy retired population, but should these levels decline overtime, to use this as a predictor of cardiovascular and cerebrovascular events, taking into account established cardiovascular risk factors.


Options:
A: Arm Label: PROOF cohort; Type: N/A; Interventions: N/A
B: Arm Label: Nicotine Replacement Therapy; Type: EXPERIMENTAL; Interventions: Drug: Nicotine replacement therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Nicotine replacement therapy; Assigned to Arm(s): Nicotine Replacement Therapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: nicotine lozenge | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: nicotine patch + nicotine lozenge | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bupropion | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: bupropion + lozenge | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: nicotine patch + nicotine lozenge; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 6
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine versus placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: nicotine versus placebo | Intervention Type: DRUG; Name: nicotine versus placebo; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Aging, Autonomic Nervous System Activity and Cardiovascular Events on a Prospective Cohort of Subjects Aged 65 Years
Brief Summary: The regulatory effects of the autonomic nervous system (ANS) concern almost all organs which permanently feed information back to this global biological vigilance system controlling allostasis. Heart rate fluctuations are highly dependent on ANS control, making the heart one of the best indicators of ANS activity.

Low ANS activity level is associated with severe cardiac and cerebral events, as well as to death from any cause in the general population.

This PROOF study was hence designed to evaluate ANS activity levels among a healthy retired population, but should these levels decline overtime, to use this as a predictor of cardiovascular and cerebrovascular events, taking into account established cardiovascular risk factors.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: PROOF cohort; Type: N/A; Interventions: N/A
C: Arm Label: PROOF cohort; Type: N/A; Interventions: Other: Sleep apnea/hypopnea detection | Intervention Type: OTHER; Name: Sleep apnea/hypopnea detection; Assigned to Arm(s): PROOF cohort
D: Arm Label: 1 - CBT Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational interviewing for smoking cessation, Behavioral: Cognitive behaviors therapy | Arm Label: 2 - Counseling + NRT; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interviewing for smoking cessation, Drug: CBT + NRT | Intervention Type: BEHAVIORAL; Name: Motivational interviewing for smoking cessation; Assigned to Arm(s): 1 - CBT Counseling, 2 - Counseling + NRT | Intervention Type: BEHAVIORAL; Name: Cognitive behaviors therapy; Assigned to Arm(s): 1 - CBT Counseling | Intervention Type: DRUG; Name: CBT + NRT; Assigned to Arm(s): 2 - Counseling + NRT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial
Brief Summary: Stent implantation is the best treatment in patients with acute myocardial infarction (STEMI) referred for primary angioplasty (pPCI). However the occurrence of in stent restenosis is responsible for the need of repeat intervention. Both Sirolimus-eluting stents (SES) and Paclitaxel-eluting stents (PES) have been proven to virtually abolish in-stent restenosis in elective patients in simple e more complex lesions. Both SES and PES have raised concerns regarding occurrence of late stent thrombosis, especially in complex lesion subsets or in high risk patients. The PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in primary angioplasty (PASEO) trial was a prospective, single-center, randomized trial evaluating the benefits of SES or PES as compared to BMS implantation in patients undergoing primary angioplasty for acute STEMI. From 1 October 2003 we randomized with 1:1:1 ratio, 270 patients with STEMI and treated with pPCI, to implantation of a bare metal stent (BMS n=90), PES (n=90) or SES (n=90).


Options:
A: Arm Label: 1. Resolute; Type: ACTIVE_COMPARATOR; Interventions: Device: Medtronic Endeavor Resolute | Arm Label: 2. XIENCE V; Type: ACTIVE_COMPARATOR; Interventions: Device: Abbott Xience V | Intervention Type: DEVICE; Name: Medtronic Endeavor Resolute; Assigned to Arm(s): 1. Resolute | Intervention Type: DEVICE; Name: Abbott Xience V; Assigned to Arm(s): 2. XIENCE V
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Device: Drug Eluting Stent (DES) | Intervention Type: DEVICE; Name: Drug Eluting Stent (DES); Assigned to Arm(s): A, B, C
C: Arm Label: Investigational device; Type: EXPERIMENTAL; Interventions: Device: AMS-3.0 | Intervention Type: DEVICE; Name: AMS-3.0; Assigned to Arm(s): Investigational device
D: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot-Scale Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Chronic Kidney Failure
Brief Summary: The bowel can serve as a complement to the kidneys' excretory function

A specifically formulated probiotic product comprised of defined and tested microbial strains may afford renoprotection in what has been called "enteric dialysis"® Confirm the alleviation of uremic syndrome hypothesis Determine the outcome of probiotics treatment Confirm U.S. FDA's Generally Recognized As Safe (GRAS) status - if needed


Options:
A: Arm Label: HSCB, Brooklyn, NY; Type: N/A; Interventions: N/A | Arm Label: 2. Nephrology Associates,; Type: N/A; Interventions: N/A | Arm Label: 3.New York Harbor VA Medical Center; Type: N/A; Interventions: N/A | Arm Label: 4.Hospital Juarez De Mexico; Type: N/A; Interventions: N/A | Arm Label: 5. Hospital Italiano de Buenos Aires; Type: N/A; Interventions: N/A | Arm Label: 6. National Hospital; Type: N/A; Interventions: N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cornstarch | Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Cornstarch; Assigned to Arm(s): Placebo
C: Arm Label: Dialysis patients; Type: N/A; Interventions: Dietary Supplement: Kibow Biotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Kibow Biotics; Assigned to Arm(s): Dialysis patients
D: Arm Label: SYNBIOTIC; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SYNBIOTIC | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SYNBIOTIC; Assigned to Arm(s): SYNBIOTIC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Brief Summary: Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease.

In NAFLD patients, the investigators will test the hypothesis that treatment with long chain n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and risk factors for cardiovascular disease and type 2 diabetes.


Options:
A: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Arm Label: Minocycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline | Arm Label: Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 fatty acids | Arm Label: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minocycline Plus Omega-3 fatty acids; Type: ACTIVE_COMPARATOR; Interventions: Drug: Minocycline Plus Omega-3 fatty acids | Intervention Type: DRUG; Name: Minocycline; Assigned to Arm(s): Minocycline | Intervention Type: DRUG; Name: Omega-3 fatty acids; Assigned to Arm(s): Omega-3 fatty acids | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Minocycline Plus Omega-3 fatty acids; Assigned to Arm(s): Minocycline Plus Omega-3 fatty acids
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease
Brief Summary: Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predisposes to increased risk of type 2 diabetes, increased risk of cardiovascular disease and may progress to chronic irreversible liver disease.

In NAFLD patients, the investigators will test the hypothesis that treatment with long chain n-3 fatty acid supplementation for 18 months favourably influences bio-markers for NAFLD and risk factors for cardiovascular disease and type 2 diabetes.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
B: Arm Label: 25 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: 50 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INT-747; Assigned to Arm(s): 25 mg INT-747, 50 mg INT-747 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention | Arm Label: Life style intervention, pioglitazone; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: pioglitazone | Arm Label: Life style intervention, berberine; Type: EXPERIMENTAL; Interventions: Behavioral: Life style intervention, Drug: berberine | Intervention Type: BEHAVIORAL; Name: Life style intervention; Assigned to Arm(s): Life style intervention, berberine, Life style intervention, pioglitazone, Lifestyle intervention | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Life style intervention, pioglitazone | Intervention Type: DRUG; Name: berberine; Assigned to Arm(s): Life style intervention, berberine
D: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill

Answer: D